Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.78 EUR -0.36%
Market Cap: 130m EUR

Heidelberg Pharma AG
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Heidelberg Pharma AG
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Heidelberg Pharma AG
XETRA:HPHA
Total Receivables
€6m
CAGR 3-Years
60%
CAGR 5-Years
33%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Total Receivables
€1.5B
CAGR 3-Years
-50%
CAGR 5-Years
138%
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Total Receivables
€22.6m
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Total Receivables
€4.3m
CAGR 3-Years
29%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Total Receivables
€196.9m
CAGR 3-Years
18%
CAGR 5-Years
7%
CAGR 10-Years
0%
Formycon AG
XETRA:FYB
Total Receivables
€30.8m
CAGR 3-Years
37%
CAGR 5-Years
44%
CAGR 10-Years
25%
No Stocks Found

Heidelberg Pharma AG
Glance View

Market Cap
130.1m EUR
Industry
Biotechnology

Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.

HPHA Intrinsic Value
HIDDEN
Show

See Also

What is Heidelberg Pharma AG's Total Receivables?
Total Receivables
6m EUR

Based on the financial report for Nov 30, 2024, Heidelberg Pharma AG's Total Receivables amounts to 6m EUR.

What is Heidelberg Pharma AG's Total Receivables growth rate?
Total Receivables CAGR 5Y
33%

Over the last year, the Total Receivables growth was 156%. The average annual Total Receivables growth rates for Heidelberg Pharma AG have been 60% over the past three years , 33% over the past five years .

Back to Top